Arteannuin B is primarily used in the pharmaceutical industry due to its significant antimalarial properties. It serves as a key intermediate in the synthesis of artemisinin-based combination therapies (ACTs), which are the standard treatment for Plasmodium falciparum malaria. Its structure contributes to the peroxide bridge essential for antimalarial activity, making it valuable in drug development. Additionally, research explores its potential in anti-inflammatory and anticancer applications, particularly in targeting certain tumor cell lines. Arteannuin B also supports studies on drug resistance mechanisms in malaria parasites, aiding in the design of more effective therapeutics.